Bladder Cancer Survivorship
- PMID: 30414013
- DOI: 10.1007/s11934-018-0860-6
Bladder Cancer Survivorship
Abstract
Purpose of review: Bladder cancer (BC) is the second most common genitourinary malignancy, with a growing population of survivors globally. Over the past two decades, there has been a growing awareness of not only the oncologic, but also the quality of life ramifications of a BC diagnosis, treatment, and surveillance. In the current review, the literature surrounding the many domains that encompass bladder cancer survivorship is summarized and analyzed.
Recent findings: There have been ongoing efforts to decrease perioperative morbidity, particularly in patients undergoing radical cystectomy, with mixed results. There is a growing emphasis on the short and long-term health-related quality of life (HR-QoL) impacts of bladder cancer spanning the domains of physical and mental QoL related to urinary function, sexual function, and financial and psychological burden, with validated measures specific to BC patients. There continue to be disparities in oncologic outcomes by race and gender. The impact of BC is prolonged and there is an unmet need for long term support and survivorship resources to address this. There is a growing global population of bladder cancer patients, and their needs are complex and vary by stage, treatment, and certain demographic features. Outcome-centered perioperative strategies show potential to diminish treatment morbidity, and validated BC specific HR-QoL tools have helped to define the impact and burden of BC, but there continue to be large areas of unmet need that warrant greater study and intervention.
Keywords: Bladder cancer; Bladder cancer disparities; Bladder cancer quality of life; Bladder cancer survivorship; Bladder cancer urinary diversion; Cancer survivorship; Sexual dysfunction; Survivorship programs; Urothelial carcinoma.
Similar articles
-
Muscle invasive bladder cancer: examining survivor burden and unmet needs.J Urol. 2014 Jan;191(1):48-53. doi: 10.1016/j.juro.2013.07.062. Epub 2013 Jul 30. J Urol. 2014. PMID: 23911603 Free PMC article.
-
Prospective comparison of quality-of-life outcomes between ileal conduit urinary diversion and orthotopic neobladder reconstruction after radical cystectomy: a statistical model.BJU Int. 2014 May;113(5):726-32. doi: 10.1111/bju.12440. Epub 2013 Dec 2. BJU Int. 2014. PMID: 24053658
-
Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory.Support Care Cancer. 2019 Oct;27(10):3877-3885. doi: 10.1007/s00520-019-4649-z. Epub 2019 Feb 14. Support Care Cancer. 2019. PMID: 30767131 Free PMC article.
-
Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence.BMC Urol. 2020 Jun 3;20(1):64. doi: 10.1186/s12894-020-00634-1. BMC Urol. 2020. PMID: 32493286 Free PMC article.
-
Factors Related to Adaptation to Cystectomy With Urinary Diversion: An Integrative Review.J Wound Ostomy Continence Nurs. 2016 Sep-Oct;43(5):499-508. doi: 10.1097/WON.0000000000000269. J Wound Ostomy Continence Nurs. 2016. PMID: 27607746 Review.
Cited by
-
Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes.Sci Rep. 2024 May 7;14(1):10482. doi: 10.1038/s41598-024-61302-0. Sci Rep. 2024. PMID: 38714855 Free PMC article.
-
PGM1 and ENO1 Promote the Malignant Progression of Bladder Cancer via Comprehensive Analysis of the m6A Signature and Tumor Immune Infiltration.J Oncol. 2022 Feb 24;2022:8581805. doi: 10.1155/2022/8581805. eCollection 2022. J Oncol. 2022. PMID: 35251177 Free PMC article.
-
The Role of Adjuvant Single Postoperative Instillation of Gemcitabine for Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.Diagnostics (Basel). 2022 May 6;12(5):1154. doi: 10.3390/diagnostics12051154. Diagnostics (Basel). 2022. PMID: 35626309 Free PMC article. Review.
-
Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer.Int J Mol Sci. 2023 Apr 1;24(7):6610. doi: 10.3390/ijms24076610. Int J Mol Sci. 2023. PMID: 37047581 Free PMC article.
-
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.BMJ Open. 2024 Jun 10;14(6):e076763. doi: 10.1136/bmjopen-2023-076763. BMJ Open. 2024. PMID: 38858157 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous